Our Mission

Greg is the President of EmVenio Research and Professional Case Management (PCM), where he leads strategic growth and operational excellence across both the Clinical Research and Healthcare Divisions. With over 20 years of experience in healthcare and clinical research, Greg has played a key role in shaping industry standards and expanding access to care through innovative, community-based delivery models.

He holds a B.S. in Business Administration from Metropolitan State University and an MBA from the University of Colorado. Greg is passionate about advancing patient-centered research and building high-performing teams that drive meaningful impact in the communities they serve.

Mark McKenzie, M.D., is EmVenio’s Chief Medical Officer, overseeing the research site network across operations, feasibility, regulatory, recruitment, training, and medical affairs. With more than two decades as a Principal Investigator and medical leader, he advances evidence‑based processes, safety oversight, and patient‑centric practices that raise quality, consistency, and engagement across site‑based models.

He holds a B.A. and B.S. from Southern Adventist University and an M.D. from the Medical College of Ohio at the University of Toledo. Dr. McKenzie is dedicated to improving trial efficiency and equitable access.

Jeff Huntsman is EmVenio’s Chief Commercial Officer, leading commercial strategy, go to market execution, and revenue performance across therapeutic areas and geographies. With 30+ years guiding global commercial teams in clinical development, real world evidence, and regulatory markets, he forges partnerships with sponsors, CROs, and sites that solve trial delivery challenges and improve predictability and patient access.

He earned a B.S. in Marketing and Political Science from Ball State University. Jeff is dedicated to collaborative, insights driven growth that speed trial delivery and advances equitable access for patients to clinical research.

Tajuana Barron is EmVenio’s Vice President of Project Management, accountable for on‑time, on‑budget delivery across global clinical programs and portfolios. With 30+ years in pharma and CRO settings, she has guided strategic partnerships, decentralized trial strategies, risk‑based oversight, and high‑performing teams coordinating start‑up, recruitment, and execution to meet sponsor milestones and quality endpoints.

She earned a B.S. in Chemistry from Bennett College and pursued graduate studies at the University of Medicine and Dentistry of New Jersey. Tajuana is committed to operational excellence, proactive collaboration, and continuous improvement that accelerate studies and advance clinical research.

Tom O’Connor is the Senior Vice President of Global Business Solutions at EmVenio, bringing 30+ years of leadership in healthcare, technology, life sciences, and clinical trials. Since 2013, he has led multiple departments, including operations, M&A, quality, business development, budgeting, global expansion, and technology enabled services, standardizing processes that help sponsors scale compliant research across countries, indications, and complex study designs.

He holds a B.A. in Economics and Political Science from the University of North Carolina. Tom's personal experience with clinical research has made him a promotor of data informed delivery models that broaden access to high quality clinical research for patients and communities worldwide.

Christy Crase serves as EmVenio’s Chief Legal Officer, overseeing Legal and Compliance. Since 2019 she has been ensuring ethical, legal and contractual excellence across the organization. With almost 30 years of practice (18 of which have been in healthcare law), she strengthens enterprise wide risk management, privacy practices, and governance frameworks that protect participants, support investigators, and enable compliant partnerships with sponsors and sites.

She holds a B.A. in Political Science and Spanish from Regis University and a J.D. from Texas Tech School of Law. Christy is committed to transparent, principled practices that enable trustworthy, patient focused clinical research.

Charlie Billings is EmVenio’s Chief Information Officer, directing enterprise technology, cybersecurity, data privacy, and compliance since 2019. With more than 7 years in healthcare and research and 25 years in IT, he has modernized infrastructure, implemented CIS Controls, and advanced alignment with HIPAA, GDPR, CCPA, and 21 CFR Part 11 to safeguard data and study integrity.

He holds a B.A. in Psychology from Boston University and an M.S. in Management and Public Policy from Carnegie Mellon University. Charlie is committed to secure, scalable platforms and resilient data practices that protect patients, enable sponsor confidence, and accelerate high‑quality clinical research at global scale.

Curtis Fletcher is EmVenio’s Chief Financial Officer, overseeing finance, treasury, accounting, and capital planning since 2010 to support sustainable growth. With over three decades of financial leadership in services and technology, he strengthens controls, forecasting, and investment discipline, aligning resources to expand research capacity, enhance systems, and enable scalable operations for sponsors and patients.

He holds a B.A. in Political Science from Wake Forest University and an MBA from the University of Alabama and is a licensed CPA. Curtis is dedicated to rigorous stewardship that funds innovation and ensures reliable, patient‑centric clinical research at global scale.

Sarah Zwicky is EmVenio’s Chief Marketing Officer, leading global marketing strategy to support pharmaceutical and clinical research services worldwide. She brings more than 25 years of experience in healthcare and life sciences solutions, with senior leadership roles spanning the homecare, medical staffing, and pharmaceutical development and commercialization sectors.

Sarah holds a Bachelor of Science degree from the University of Wisconsin–Madison. She is deeply committed to advancing patient-centered innovation by building high-performing teams and delivering integrated communications strategies that accelerate clinical research development and improve healthcare outcomes.

Beth Perez is EmVenio’s Chief of Staff, guiding enterprise alignment, strategic execution, and organizational clarity as the company scales. With more than 25 years of experience in healthcare strategy, business operations, and partnerships, she has led growth and transformation across multiple healthcare organizations. including DaVita, where she also served as Chief of Staff to the COO.

She holds a B.A. in Psychology from the University of Pennsylvania and an MBA from the Tuck School of Business at Dartmouth College. Beth is committed to fostering cross‑functional alignment and mission‑driven collaboration that strengthens EmVenio’s impact on patient‑centered clinical research.

Brad Drevno is EmVenio’s Chief Operating Officer, responsible for operational strategy, scalability, and performance across the shared services. Since 2016, he has applied 30+ years of leadership to optimize processes, strengthen global operations, and deploy standardized playbooks that improve speed, quality, and reliability.

He holds a B.S. in Business and Economics from California State University. Brad is passionate about building high performing teams and systems that deliver consistent, patient friendly trial experiences.

Jennifer Hoffman is EmVenio’s Vice President of Human Resources and Talent Acquisition, overseeing recruitment, benefits, employee relations, and organizational development. Since 2019, she has leveraged multi‑site HR leadership to scale a mission‑aligned workforce, implemented talent pipelines, and evolved programs that support rapid growth and complex clinical operations.

She holds a B.S. in Communications from the University of Utah and is Myers‑Briggs certified. Jennifer is committed to a people‑first culture that attracts, develops, and retains talent to advance clinical research and patient access.